<DOC>
	<DOCNO>NCT00666965</DOCNO>
	<brief_summary>The primary objective study investigate efficacy safety SPM 962 Japanese RLS patient multi-center , placebo-controlled double-blind parrallel group comparative study follow once-daily multiple transdermal dos SPM 962 within range 2.25 6.75 mg/day . Recommended maintainance dose range also investigate .</brief_summary>
	<brief_title>A Placebo-Controlled Study SPM 962 Restless Legs Syndrome ( RLS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>1 . Subject 20 less 80 year age able think her/his participation time informed consent . 2 . Subject meet diagnosis idiopathic RLS base 4 cardinal clinical feature accord IRLSSG/NIH . 3 . The following subject include study Subject currently receive treatment RLS . Subject previously receive treatment either Ldopa dopamine agonist efficacy observe either drug . 4 . At baseline , subject score ≧ 15 IRLS sum score RLS symptom occur twice week ( ≧score 2 IRLS Question 7 ) 5 . Subject score ≧ 4 CGI Severity score baseline 1 . Subject secondary RLS association renal impairment uremia，iron deficiency anemia , drug associate symptom . 2 . Subject , suspected history sleep disorder sleep apnea syndrome , narcolepsy , sleep attacks/sudden onset sleep . 3 . Subject additional clinically relevant concomitant disease symptoms polyneuropathy ( include diabetic neuropathy ) , akathisia，claudication varicoses，muscle fasciculation，painful leg move toe radiculopathy . 4 . Subject central nervous disease like Parkinson 's disease , dimentia , progressive supranuclear paresis , multisystem atrophy , Huntington 's Chorea , amyotrophic lateral sclerosis , Alzheimer 's disease . 5 . At screen baseline , subject psychiatric condition like confusion , hallucination , delusion , excitation , deliria , abnormal behaviour . 6 . Subject orthostatic hypotension systolic BP mark ≦ 100 mm Hg decrease BP supine stand position ≧ 30 mm Hg . 7 . Subject history epilepsy , convulsion etc . 8 . Subject serious cardiac dysfunction and/or arrhythmia ( e.g. , congestive heart failure Class III IV NYHA , myocardial infarction , angina pectoris , conduction system dysregulations , second third degree AV block , complete leave bundle branch block , sicksinussyndrome , ventricular fibrillation within twelve month prior enrollment ) . 9 . Subject arrhythmia receive Class Ia antiarrhythmic drug ( e.g. , quinidine , procainamide ) , Class III antiarrhythmic drug ( e.g. , amiodarone , sotalol ) 10 . At screen baseline , subject develop serious ECG abnormality . Subjects QTcinterval &gt; 450 msec twice screen . Subject average QTcinterval two ECGs &gt; 450 msec male &gt; 470 msec female baseline . 11 . Subject long QT syndrome congenital . 12 . Subject serum potassium level &lt; 3.5 mEq/L screening . 13 . Subject total bilirubin ≧3.0 mg/dL AST ( GOT ) and/or ALT ( GPT ) great 2.5 time upper limit reference range ( ≧100 IU/L ) screening . 14 . Subject BUN ≧ 30 mg/dL serum creatinine ≧2.0 mg/dl screening . 15 . Subject history allergic reaction topical agent transdermal patch . 16 . Subject pregnant nursing woman plan pregnancy trial . 17 . Subject pursues shift work subject continuous nondiseaserelated life condition allow regular sleep night . 18 . Subject autoimmune disease , chronic active hepatitis immune deficiency disorder . 19 . Subject malignant neoplastic disease require therapy within twelve month prior screen . 19 . Subject receive investigational drug clinical trial within last 12 month prior baseline . 20 . Subject judged inappropriate trial investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>Idiopathic Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
</DOC>